Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer

R. K. Murthy, S. Loi, A. Okines, E. Paplomata, E. Hamilton, S. A. Hurvitz, N. U. Lin, V. Borges, V. Abramson, C. Anders, P. L. Bedard, M. Oliveira, E. Jakobsen, T. Bachelot, S. S. Shachar, V. Muller, S. Braga, F. P. Duhoux, R. Greil, D. CameronL. A. Carey, G. Curigliano, K. Gelmon, G. Hortobagyi, I. Krop, S. Loibl, M. Pegram, D. Slamon, M. C. Palanca-Wessels, L. Walker, W. Feng, E. P. Winer

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences